At 007 Venture Partners, we are drawn to founders who build with conviction, clarity, and care. Not just products, but infrastructure. Not just compliance, but justice.
In the US healthcare system, a system where medical interpretation is mandated by federal law yet routinely fails the patients who depend on it most, we saw not just another health AI company, but a team solving the problem that every incumbent ignores: what happens when the interpreter never arrives.
That's what Opalite Health is here to fix.
A New Kind of Medical Interpreter
Opalite Health is building what others have been too comfortable to attempt: a clinically fine-tuned, HIPAA-compliant AI interpretation platform that replaces expensive, slow, and inconsistent human interpreter services across every point of care. Not good as in "good enough." But good as in: instant, clinically superior, and designed from the ground up for the patients who need it most.
Instead of forcing clinicians and patients to wait 30+ minutes for a phone interpreter that costs hospitals millions of dollars a year, Opalite gives them an AI medical interpreter that is always available, supports 150+ languages, and has been independently validated at Johns Hopkins Medicine to outperform certified human interpreters. Medical interpretation is non-discretionary spend mandated by federal law. Opalite makes it work.
The results are already speaking for themselves: Currently growing at 55% month-on-month, with signed contracts across FQHCs, children's hospitals, specialty clinics, and health plans. And the number we keep coming back to: in a Johns Hopkins validation study, Opalite achieved severity-weighted error scores of 1 to 10 versus 266 to 1,008 for human interpreters across Cantonese, Mandarin, and Spanish, while reducing clinical conversation length by 20%. Not a marginal improvement. A clinically significant one.
From Compliance to a Healthcare Voice Platform
Opalite isn't just an interpretation tool. The platform supports 150+ languages with on-device PHI removal, full HIPAA and SOC2 compliance from day one, and deep EHR integration that reduces documentation friction across care teams. Every conversation generates labelled clinical data that improves model accuracy over time, widening the gap against off-the-shelf AI models that were never built for medical settings.
The clinical fine-tuning matters enormously. Generic AI models are hallucination-prone in clinical contexts, optimised for perhaps 30 languages, and structurally non-compliant with HIPAA at the AI layer. Opalite's model runs on-device PHI removal before any cloud processing, achieving +15% accuracy over off-the-shelf alternatives and full compliance by design, not as an afterthought. Every deployment deepens the proprietary clinical training data. That's a flywheel that neither phone relay incumbents nor generic AI providers can replicate.
And interpretation is only the beginning. The same voice AI platform that handles clinical conversations becomes the infrastructure layer for voice-first EHR documentation, multilingual patient engagement, and eventually voice biomarkers for disease detection. The combined addressable market across these categories exceeds $100B. Opalite is starting with a $16B non-discretionary compliance obligation and building toward the foundational voice infrastructure layer for all of healthcare.
Why Now
The macro environment has never been more aligned for what Opalite is building.
Medical interpretation is mandated under Title VI of the Civil Rights Act and the Affordable Care Act for any organisation receiving federal funding. This creates a non-discretionary, non-cyclical market of over 20,000 healthcare organisations in the US alone, each legally obligated to provide language access services. The dominant incumbent solution, phone and video relay services at $1 to $3 per minute, costs hospitals $1M to $5M annually, delivers inconsistent quality, and has not materially improved in decades.
Meanwhile, the supply of trained human interpreters is structurally insufficient. The populations requiring language access services are growing faster than interpreter pipelines can respond. AI is the only path to universal language access at healthcare system scale, and Opalite is the only AI interpreter with peer-reviewed clinical validation to prove it is safe enough to use.
The traditional incumbents, LanguageLine, CyraCom, AMN Healthcare, remain structurally unable to solve the cost, speed, or quality problem simultaneously because their model is built on human labour. That gap is Opalite's opening, and it is widening.
The Founders
The best founder stories are the ones where the problem is personal. Cathleen Kuo's is exactly that.
Dr. Cathleen Kuo, CEO, trained as a neurosurgeon at Johns Hopkins Medicine and Stanford Neurosurgery. She has stood at a hospital bedside waiting for a phone interpreter that took 35 minutes to connect. She has seen firsthand the care delays, the miscommunications, and the adverse outcomes that broken interpretation workflows produce. And her motivation goes beyond clinical observation: her own mother was misdiagnosed due to an incorrect medical interpretation, with significant consequences for her health. That experience is the foundation of Opalite's mission.
Before Opalite, Cathleen co-founded MedDx, a next-generation AI medical calculator platform, giving her direct prior experience building and commercialising health AI. Her clinical credibility opens doors with hospital procurement teams that no non-physician founder could replicate, and her personal connection to the problem ensures the product is built to the standard that patients and clinicians actually need.
Alex Mehregan, CTO, brings a complementary and equally specific set of skills: voice AI engineering at Apple and academic AI research at Berkeley EECS, precisely the technical depth that Opalite's core product requires. He co-founded MedDx alongside Cathleen, giving the team shared founder history and deep alignment on what it takes to build in healthcare. Within months of launching Opalite, he recruited an early engineering hire from Meta Superintelligence Labs, a signal of the technical talent the company can attract.
This is not a team theorising about healthcare problems. One has lived them at the bedside. The other has built the exact technology now being applied to solve them.
Why We Invested
At 007VP, we invest in founders solving hard problems at scale, especially those building infrastructure that serves the people most overlooked by existing systems.
Opalite fits that mission precisely. It is a capital-efficient, clinically validated, and mission-driven company targeting a legally mandated market that cannot be disrupted by budget cycles or executive preference. 55% month-on-month growth from a standing start is exceptional velocity at this stage. The largest contract closed in month four via a cold pitch at a conference. Multiple same-day signings validated a conference GTM model that keeps customer acquisition costs highly favourable. And the pipeline includes some of the largest health systems in the country.
We are proud to invest alongside YC, Rebel Fund, Robinhood Ventures, and a strong network of physician angels including practising MDs with direct experience in the workflows Opalite is transforming.
But more than the metrics and the cap table, we believe in what Cathleen and Alex stand for.
We believe every patient deserves access to accurate medical communication regardless of the language they speak. We believe that a product validated at Johns Hopkins to outperform certified human interpreters, at a fraction of the cost, is not a marginal improvement but a genuine step change in the standard of care for underserved populations. And we believe that $650K ARR in five months is not a lucky outcome. It is the clearest signal we have seen in years that a product has found genuine, urgent, recurring utility.
That is what Opalite Health is building.
The Road Ahead
The vision is bold. The execution so far has been even bolder.
With a clear path to $5M ARR by Q4 2026 driven by pipeline conversion and accelerating conference GTM, and a longer-term roadmap through health system expansion, EHR integration, and voice biomarkers, Opalite is positioned to define the category of clinical voice AI for the next decade.
The platform also carries deep impact credentials. Language barriers are a primary driver of health inequity. Patients with limited English proficiency experience higher rates of misdiagnosis, medication errors, and adverse events. Opalite removes that barrier at every point of care, making the standard of care received by an English-speaking patient available to every patient regardless of the language they speak. The mission aligns closely with UN Sustainable Development Goals 3, 10, 16, and 17, and sits at the intersection of healthcare access, civil rights compliance, and AI-native infrastructure.
As the team expands its health system pipeline, deepens its clinical data advantage, and builds toward the broader voice infrastructure opportunity, we are proud to support Cathleen, Alex, and the Opalite team on this journey.
Because when you give a patient the ability to communicate clearly with their doctor for the first time, you don't just improve an encounter. You change what healthcare means for an entire community.
And that's what Opalite Health does.
